首页|吡拉西坦联合尼莫地平对脑梗塞后血管性痴呆的治疗效果观察

吡拉西坦联合尼莫地平对脑梗塞后血管性痴呆的治疗效果观察

扫码查看
目的 对吡拉西坦联合尼莫地平对脑梗塞后血管性痴呆的治疗效果进行观察和分析.方法 选取2009年2月~2012年3月期间,首都医科大学附属北京朝阳医院收治的32例脑梗塞后血管性痴呆患者,其中19例为男性,13例为女性,年龄为63~84岁.随机将上述患者分为2组,每组各16例.给予治疗组患者口服尼莫地平联合吡拉西坦片治疗,给予对照组患者口服尼莫地平治疗.结果 治疗组的有效率为93.8%、不良反应率为6.3%,而对照组有效率为81.2%、不良反应率为18.8%,2组差异明显(P<0.05).结论 在对脑梗塞后血管性痴呆患者的治疗中,使用吡拉西坦联合尼莫地平具有显著的疗效和更小的不良反应率.
Observation on therapeutic effect of Laci Staw combined with nimodipine on vascular dementia after cerebral infarction
Objective To observe the effect of nimodipine combined with nimodipine on cerebral vascular dementia after cerebral infarction.MethodsFrom February 2009 to March 2012, 32 patients with vascular dementia after cerebral infarction were selected in Beijing Chaoyang hospital.Among them, there were 19 males and 13 females, aged 63~84 years old.The patients were randomly divided into two groups, each group of 16 patients.The patients in the treatment group were treated with oral nimodipine combined with Piracetam Tablets.ResultsThe effective rate of the treatment group was 93.8%, the adverse reaction rate was 6.3%, while the control group was effective, the adverse reaction rate was 18.8%, the difference between the two groups was significant (P<0.05).ConclusionIn the treatment of patients with vascular dementia after cerebral infarction, the use of nimodipine combined with nimodipine has significant curative effect and less adverse reaction rate, which is worthy of clinical application.

piracetamnimodipinecerebral infarctionvascular dementia

李涛、杨新乾、李锦平、赵奇煌

展开 >

首都医科大学附属北京朝阳医院 神经外科,北京 100020

吡拉西坦 尼莫地平 脑梗塞 血管性痴呆

2017

中国生化药物杂志
南京生物化学制药研究所,全国生化制药情报中心站,中国生化制药工业协会,中国药品生物制品检定所

中国生化药物杂志

ISSN:1005-1678
年,卷(期):2017.37(6)
  • 16
  • 6